NeoGenomics Operating Income from 2010 to 2026
| NEO Stock | USD 12.47 0.04 0.32% |
Operating Income | First Reported 1999-03-31 | Previous Quarter -47.6 M | Current Value -27 M | Quarterly Volatility 12.8 M |
Check NeoGenomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeoGenomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 87.6 M, Interest Expense of 8 M or Selling General Administrative of 272.7 M, as well as many indicators such as Price To Sales Ratio of 0.69, Dividend Yield of 0.0059 or PTB Ratio of 0.51. NeoGenomics financial statements analysis is a perfect complement when working with NeoGenomics Valuation or Volatility modules.
NeoGenomics | Operating Income | Build AI portfolio with NeoGenomics Stock |
Latest NeoGenomics' Operating Income Growth Pattern
Below is the plot of the Operating Income of NeoGenomics over the last few years. Operating Income is the amount of profit realized from NeoGenomics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of NeoGenomics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. NeoGenomics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeoGenomics' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
NeoGenomics Operating Income Regression Statistics
| Arithmetic Mean | (36,691,002) | |
| Geometric Mean | 10,699,694 | |
| Coefficient Of Variation | (151.99) | |
| Mean Deviation | 49,143,414 | |
| Median | (971,000) | |
| Standard Deviation | 55,764,905 | |
| Sample Variance | 3109.7T | |
| Range | 170.6M | |
| R-Value | (0.74) | |
| Mean Square Error | 1520.5T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (8,127,066) | |
| Total Sum of Squares | 49755.6T |
NeoGenomics Operating Income History
Other Fundumenentals of NeoGenomics
NeoGenomics Operating Income component correlations
Click cells to compare fundamentals
About NeoGenomics Financial Statements
NeoGenomics investors utilize fundamental indicators, such as Operating Income, to predict how NeoGenomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -82.9 M | -78.8 M | |
| Non Operating Income Net Other | -244.9 K | -232.7 K |
Pair Trading with NeoGenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.Moving together with NeoGenomics Stock
| 0.73 | GH | Guardant Health Sell-off Trend | PairCorr |
Moving against NeoGenomics Stock
| 0.77 | 300015 | Aier Eye Hospital | PairCorr |
| 0.77 | HIMS | Hims Hers Health | PairCorr |
| 0.75 | SPI | Spire Healthcare | PairCorr |
| 0.74 | DVA | DaVita HealthCare | PairCorr |
| 0.6 | MNDR | Mobile health Network | PairCorr |
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of NeoGenomics Correlation against competitors. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.